Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.36 |
| ▸ | RAF1 | P04049 | 14/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.33 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
| ▸ | PPID | Q08752 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776442 | 0.86 | CA2 (0.36) | BRAFRAF1CA2CA9 | |
| SCHEMBL16776433 | 0.82 | RHOA (0.34) | BRAFRAF1CA2CA9 | |
| SCHEMBL16776430 | 0.80 | CA2 (0.32) | BRAFRAF1CA2CA9 | |
| SCHEMBL16776322 | 0.79 | NPC1 (0.44) | BRAFRAF1CA2CA9 | |
| SCHEMBL16776179 | 0.78 | CA2 (0.45) | CA2CA9TDP1 | |
| SCHEMBL16776165 | 0.78 | CA2 (0.43) | RAF1CA2CA9TDP1 | |
| SCHEMBL16776476 | 0.78 | CA2 (0.43) | BRAFCA2CA9 | |
| SCHEMBL16776412 | 0.78 | FYN (0.41) | BRAFRAF1CA2CA9 | |
| SCHEMBL16776432 | 0.77 | CA2 (0.40) | RAF1CA2CA9 | |
| SCHEMBL16775868 | 0.77 | CA2 (0.43) | BRAFRAF1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | BRAF 3419/4885RAF1 2875/4885CA2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.